A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants

• DOI: 10.1016/j.isci.2022.103960
• Publication Date: 2022-02-22T23:18:07Z
• Authors: Jules B. Weinstein; Timothy A. Bates; Hans C. Leier; Savannah K. McBride; Eric Barklis; Fikadu G. Tafesse
• Keywords: Applied microbiology; 0301 basic medicine; 03 medical and health sciences; Science; Q; Nanotechnology; Bioengineering; Article; 3. Good health

AbstractThe spike glycoprotein of SARS-CoV-2 engages with human angiotensin-converting enzyme 2 (ACE2) to facilitate infection. Here, we describe an alpaca-derived heavy chain antibody fragment (VHH), saRBD-1, that disrupts this interaction by competitively binding to the spike protein receptor-binding domain. We further generated an engineered bivalent nanobody construct engineered by a flexible linker, and a dimeric Fc conjugated nanobody construct. Both multivalent nanobodies blocked infection at picomolar concentrations and demonstrated no loss of potency against emerging variants of concern including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Epsilon (B.1.427/429), and Delta (B.1.617.2). saRBD-1 tolerates elevated temperature, freeze-drying, and nebulization, making it an excellent candidate for further development into a therapeutic approach for COVID-19.